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Abstract
Objective: To describe the long-term outcomes of Acute Myeloid Leukemia (AML) and to study
clinicopathological features at presentation, morphological subtypesand remission rates.
Methods: Demographic information, response to therapy and survival of patients (>14 years of age)
admitted between January 1988 to August 1996 with acute myeloid leukaemia was retrieved and
analysed.
Results: Seventy-four patients were admitted with a diagnosis of AML during the study period. There
were 43 males and 31 females. Age ranged between 15 and 70 years with a mean age of 38 years. The
most common presenting feature was fever (67.5%) and the morphological subtype according to
French-American-British Group (FAB) criteria was M4. Fifty-five patients received treatment and were
evaluable for response and outcomes. Thirty-six (65.4%) patients had complete remission. Sixteen
(29.1%) died during the first 28 days after starting induction chemotherapy. The median survival was
11 months. Six (11%) patients (4 females, 2 males) are surviving beyond 4 years (long-term survivors).
Conclusion: Our study suggests that the long-term outcomes of adults with AML are comparable to
what has been reported in the literature for patients who do not receive bone marrow transplants (JPMA
52:482;2002).
Introduction
Acute myeloid leukemia (AML) constitutes 12% of acute leukemias under the age of 10 years, 28%
between ages 10-15 years and 80-90% of cases in adults1. Whereas the mean age at presentation is 55
years, the incidence increases with age2. A remission rate of 50-70% has been observed with the
current chemotherapeutic regimens and supportive care3, However, the vast majority of patients relapse
and only 10-15% live for five years or more after the diagnosis4-6. These figures are derived from
studies conducted in North America and Western Europe and may not reflect the pattern of disease in
the developing world. It is known that there are some important differences amongst patients due to
ethnic, socioeconomic and environmental factors7. The Aga Khan University Hospital is a tertiary
referral and a specialist haematology center. Patients are referred from all over the country, the majority
being from the regional areas. In this report, we present the clinicopathological features, remission rates
and long-term outcomes of AML in adults in Pakistan.
Patients and Methods
The data were collected retrospectively and covered a study period between January 1988 and August
1996. Consecutive patients diagnosed to have AML and admitted to the hospital were enrolled. The
medical records of all the patients above the age of 14 years were retrieved. The diagnosis was logged
on the face sheet by the admitting Physician. The medical records department uses International
Classification of Diseases (lCD) version 9.0. The patients were followed up till the end of December
2001 and hence a minimum of 40 months of follow up was available on all the patients. The

chemotherapy regimens are as under: Induction chemotherapy with Cytosine arabinoside (PharmaciaUpjohn, Stockholm, Sweden) 100 rng/m2 continuous intravenous infusion for 7 days and either
Daunorubicin (Pharmacia-Upjohn, Stockholm, Sweden) 45 mg/rn2 intravenous bolus for 3 days or
Mitoxantrone (Lederle, Baulkham Hills, Australia) 12 mg/m2 intravenous bolus for 3 days. Etoposide
(Bristol Myers-Squibb SpA, Latina, Italy) 100 mg/m2 was administered as intravenous infusion over 2
hours for 4 days in addition to the induction regimens for patients with M4 or MS FAB (FrenchAmerican-British classification) subtypes8. Remission status was checked on the 10th day and after 3
weeks of induction chemotherapy. Six patients with M3 FAB subtype received All-trans retinoic acid
(ATRA) (Hoffman-La Roche, Paris, France) at dose of 45 mg/m2 either alone (n=3) or in conjunction
with chemotherapy (n3)9 for induction of remission. Once patients were in remission, two courses of
consolidation chemotherapy were given, consisting of cytosine arabinoside 100 mg/m2 for 5 days and
either Daunorubicin 45 mg/m2 for 2 days or Mitoxantrone 12 mg/m2 for 2 days. High-dose Cytosine
arabinoside at a dose of 3.0gm! m2 per day in two divided doses for 3 days was administered for
consolidation of remission10. A total of 3 courses were given at an interval of 3-4 weeks. The data are
expressed as meanES.D. and as percentages where appropriate. Kaplan and Meier curves were used for
survival analysis11.
Results
Between January 1988 and August 1996, a total of 74 patients above the age of 14 years were admitted
to the hospital with an underlying diagnosis of AML. There were 43 males and 31 females with a male
to female ratio ofcommonest presenting symptom was fever (67.5%), followed by the symptoms of
anaemia (45.9%) and bleeding (29.7%). Other significant presenting features included admission at our
hospital and were admitted with a septic episode while two had intra-cerebral bleed. A total of 55
patients received chemotherapy and were evaluable for response and toxicity. Thirty-six out of 55
(65.4%) patients entered complete remission (CR). Sixteen (29.1%) died during the first 28 days after
starting induction chemotherapy (early mortality). The median survival was 11 months. The overall
survival of these patients is shown in Figure. Two patients received allogenic bone marrow
transplantation in the UK, however, their overall survival was 6 and 12 months only.1.3:1.0. Their ages
ranged between 15 and 70 years. The mean age at the time of diagnosis was 38 years. The anorexia,
weight loss, fatigue and headaches. One patient was diagnosed incidentally.
Overall 55 (74.3%) had fever. Only 30 (40%) had a microbiological focus and 17 (22%) patients had a
clinical source of infection. The commonest morphological subtype according to the FAB criteria8 was
M4, details are shown in Table 1.

The haematological and biochemical features are shown in Table 2.

The mean haemoglobin concentration was 8.3 gm!dl, mean leukocyte count was 49.7x109/L and the
mean platelet count was 65.5x109/L. Fifty-three (71.5%) patients had haemoglobin (Hb) <10 gm/dl
while 13 (18.9%) presented with a total leukocyte count (TLC) >100 x 109/L (hyperleukocytosis).
Mean lactate dehydrogenase (LDH) level was 1520 IU/L.
Ten (13.5%) patients did not receive treatment and left hospital after the diagnosis because of several
reasons including financial constraints. Nine (12.2%) patients died before the treatment could be
commenced at our hospital. Seven of these patients presented with signs of sepsis. Out of these 9
patients, 5 had pneumonia, and two had received chemotherapy prior to admission at our hospital and
were admitted with a septic episode while two had intra-cerebral bleed. A total of 55 patients received
chemotherapy and were evaluable for response and toxicity. Thirty-six out of 55 (65.4%) patients
entered complete remission (CR). Sixteen (29.1%) died during the first 28 days after starting induction
chemotherapy (early mortality). The median survival was 11 months. The overall survival of these
patients is shown in Figure. Two patients received allogenic bone marrow transplantation in the UK,
however, their overall survival was 6 and 12 months only.
Six (fl%) patients are surviving beyond 4 years (long-term survivors). Of these 4 are female and 2
males. One patient developed non-Hodgkins lymphoma (NHL) 3 years after diagnosis. He went into
complete remission after receiving chemotherapy for NHL for two years. He remains alive with CNS
disease. One patient had M2 FAB subtype, 2 had M3, 2 M4 and one M5 subtype. Only one patient
presented with hyperleukocytosis. The same patient had trisomy 8 on karyotyping. Age, gender, FAB
subtype, presenting Hb. TLC, platelets, LDH, bilirubin and creatinine were tested and found not
significant on univariate analysis for long-term survival. The features of long-term survivors are shown
in Table 3.

Discussion
There is very little information available from developing Asian countries including Pakistan about the
outcome of AML treatment. We undertook this study to examine the features of long-term survivors
after treatment for AML. Several clinical and laboratory features at presentation were studied to see
whether these predict for long-term survival.
FAB Cooperative Group classification is now universally accepted as the basic morphologic criteria to
study different aspects of acute leukaemia8. In our study, M4 was the most predominant FAB subtype
(46%), followed by M2 (16%), M3 (15%) and MS (9.5%). Our findings are consistent with the Eastern
Cooperative Oncology Group experience12. However, they are at variance with some other (Table 1).
In all these studies the predominant subtype was M2. M5 was noted to be the commonest subtype in
the studies of Mertelsmann et al14 and van der Reijden et al15. It is shown that AML FAB M4 is
common in Australian population compared to Japanese, where FAB M2 is a common AML subtype18
suggesting a possible genetic susceptibility to a particular subtype of acute myeloid leukaemia. It is
thus likely that certain genetic factors as MLL gene rearrangement play a role in causing a particular
FAB subtype of AML in our population. For example, MLL (ALL-i) gene has been associated with
AML FAB subtype M4 in Italian population particularly in young adults and children19.
The mean age at presentation is also at variance with several studies where the mean age at
presentation of patients with AML is described as 50 years with incidence increasing with age20.
Environmental factors such as viruses and pollutants in the food chain or genetic factors possibly play a
role in causing AML at a younger age in our patients.21,22
The clinicopathological features in our patients reveal that the disease was observed to be at an
advanced stage at the time of presentation. In our patients the mean value of Hb. was 8.3 gm/dl which
is lower than the mean value of Hb. reported by Sultan et al13. Similarly the mean platelet count (65.2
X 109/L) was also lower as compared to the mean platelet count (82 X 109/L) reported by same
authors13.
Fever (67.5%) and infection (39% clinical and 22% microbiological) were found to be greater as
compared to those reported by Keating et al23 where fever (34%) and infection (clinical 16% and
microbiological 22%) were not the major presenting features. This could be because of late
presentation of patients at our hospital, which is a tertiary care center. The remission rate of 65% is
comparable with the Eastern Cooperative Oncology Group experience of 57%24, North American

Marrow transplant group reported a disease-free survival of 49% and University of Minnesota Masonic
cancer centre reported disease-free survival of 28%25 in the patients treated with chemotherapy alone.
The better long-term disease-free survival figures in these studies are probably due to use of high-dose
cytosine arabinoside along with daunorubicin after the patient entered remission. We on the other hand
used high-dose cytosine arabinoside alone in most of our patients once they entered remission. On the
contrary M.D. Anderson cancer centre group reports a long-term remission rate of l0.7%26. Southwest
oncology group reported a long-term disease-free survival of 21% when they used high-dose cytosine
arabinoside for induction and during consolidation therapy27. They further report that when standarddose cytosine arabinoside was used for induction and high-dose cytosine arabinoside for consolidation
the long-term disease-free survival rate fell to 11%. They also reported that in the cohort of patients in
which standard-dose cytosine arabinoside was used for both induction and consolidation therapy the
long-term disease-free survival was only 6%. The better survival in the group of patients receiving
high-dose cytosine arabinoside for induction and consolidation was at a cost of greater toxicity and
mortality. In the group of patients receiving high-dose cytosine arabinoside the toxicity rate was 14%
compared to 5% in the group which received standard-dose cytosine arabinoside28. In this study we
reported the long-term disease-free survival of 11% and we too used standard-dose cytosine
arabinoside for induction and high-dose cytosine arabinoside for consolidation therapy. The Memorial
Sloan-Kettering cancer centre and Southeastern cancer study group reports a long-term disease-free
survival of 15% in the group of patients treated with idarubicin and cytosine arabinoside and 7% in the
group of patients treated with daunorubicin and cytarabine as induction chemotherapy29. We however,
found a long-term survival of 11 % when we used daunorubicin and cytosine arabinoside as induction
chemotherapy. Bennett et al. reported a long-term survival of 19.3% when they used standard-dose
cytosine arabinoside and daunorubicin30.
Six (11%) of our patients are surviving equal to or beyond 4 years without disease. Our results of longterm disease-free survival are comparable to most published studies on this subject. We however, report
a high early mortality rate of 29% and this is probably due to late presentation. Majority of our patients
had sepsis at the time of presentation and as many as 30 (54.5%) had high leukocyte count of greater
than 20x109/L and 43 (78.1%) had haemoglobin lower than 10 gm/dl. It is reported that female gender,
leukocyte count less than 10x109/L and haemoglobin greater than 10 gm/dl are associated with longer
disease-free survival30.
Univariate analysis of various factors failed to predict long-term survival in our group of patients. A
level of statistical significance may have been achieved due to either a small sample size or to a
different nature of the disease.
In conclusion our data shows that long-term survival of adults with AML when treated with
chemotherapy alone is comparable to what has been reported in the literature, We did not find any
factor that may predict long-term survival in these patients.
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